Nitroprusside

Summary

Nitroprusside (CHEMBL2097081) is an approved small molecule (ATC C02DD01); indicated across 6 conditions including hypertensive disorder and myocardial infarction.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: C02DD01
• Indications: 6 conditions
• Clinical trials: 14

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2097081
Name	Nitroprusside
Type	Small molecule
Max phase	4
ATC	C02DD01

Also known as: Nitroprusside, nitroprusside, SID29217813, NITROPRUSSIDE, SODIUM NITROPRUSSIDE DIHYDRATE

Parent form; salt/anhydrous children: CHEMBL136478, CHEMBL3183086

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

6 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
hypertensive disorder	4	MONDO:0005044	EFO:0000537
myocardial infarction	2	MONDO:0005068	EFO:0000612
hypotensive disorder	2	MONDO:0005468	EFO:0005251
depressive disorder	2	MONDO:0002050	MONDO:0002050
orthostatic hypotension	1	MONDO:0005469	EFO:0005252
postural orthostatic tachycardia syndrome	1	MONDO:0011479	EFO:1000645

Clinical trials

Total trials: 14.

Phase distribution

Phase	Trials
Not specified	5
PHASE2	4
PHASE4	2
PHASE2/PHASE3	1
PHASE1	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00128791	PHASE4	TERMINATED	Nitroprusside for Prevention of no-Reflow in Primary Angioplasty
NCT03743103	PHASE4	TERMINATED	Esmolol for the Treatment of Hypertension After Intracerebral Hemorrhage Study (ETHICHS)
NCT00590070	PHASE2/PHASE3	COMPLETED	THE REOPEN-AMI STUDY - Intracoronary Nitroprusside Versus Adenosine in Acute Myocardial Infarction
NCT00135668	PHASE2	COMPLETED	Dose-response Study of Sodium Nitroprusside in Children Requiring Controlled Hypotension in the Operating Room
NCT00535808	PHASE2	COMPLETED	Effect of Strategy for Blood Pressure Control on Cerebral Oxygen Balance During Aortic Coarctation Repair: A Randomized Study
NCT00621816	PHASE2	COMPLETED	Sodium Nitroprusside for Blood Pressure Reduction in the ICU (SNP2)
NCT03102736	PHASE2	COMPLETED	Ketamine and Nitroprusside for Depression
NCT00748059	PHASE1	COMPLETED	The Pathophysiology of Orthostatic Hypotension
NCT06520982	EARLY_PHASE1	RECRUITING	Early Neurovascular Adaptations in Aging Women
NCT00168519	Not specified	COMPLETED	Contraction (Exercise) Mediated Glucose Uptake as a Therapeutic Target in Type 2 Diabetes
NCT00226096	Not specified	COMPLETED	Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage
NCT01125943	Not specified	COMPLETED	Bevacizumab and Endothelium Dependent Vasodilation
NCT02001298	Not specified	COMPLETED	Remifentanil and Nitroprusside for Controlled Hypotension
NCT02123069	Not specified	COMPLETED	Vascular Function and Uterine Fibroids

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).